Shares of CureVac (NASDAQ:CVAC - Get Free Report) shot up 4.7% during trading on Thursday . The stock traded as high as $4.32 and last traded at $4.26. 356,735 shares traded hands during trading, a decline of 79% from the average session volume of 1,710,864 shares. The stock had previously closed at $4.07.
CureVac Stock Down 1.9 %
The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $917.91 million, a price-to-earnings ratio of 7.45 and a beta of 2.50. The stock has a 50 day moving average of $3.18 and a 200 day moving average of $3.17.
Institutional Investors Weigh In On CureVac
A number of institutional investors have recently made changes to their positions in the company. Private Advisor Group LLC acquired a new position in CureVac in the third quarter worth $30,000. International Assets Investment Management LLC bought a new position in shares of CureVac in the 3rd quarter worth about $35,000. Integrated Wealth Concepts LLC acquired a new position in shares of CureVac in the 3rd quarter valued at about $35,000. Bank of New York Mellon Corp acquired a new position in shares of CureVac in the 2nd quarter valued at about $54,000. Finally, Barclays PLC bought a new stake in shares of CureVac during the 3rd quarter valued at about $67,000. 17.26% of the stock is currently owned by institutional investors.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
